Abstract
Introduction
Neuropathy represents the most frequent complication of diabetes mellitus, affecting sensitive, motor and vegetative nerves . The (1) prevalence of diabetic neuropathy is estimated to be approximately 50% after a 20 year history of diabetes . Symmetric distal (2) diabetic polyneuropathy represents 75% of the total number of diabetic neuropathies and constitute an element of gravity in the prognosis of the diabetic patient because it leads to foot ulcerations that frequently develop infection and often lead to amputation.
It is well known that diabetes mellitus represents the leading cause globally for n o n -t r a u m a t i c l i m b a m p u t a t i o n .
Hyperglycaemia is the most important cause of increased oxidative stress in the diabetes patient, free radicals having the capacity to affect cellular membranes rich in lipids, with the generation of some products named lipoperoxides . Oxidative stress represents (3) one of the most important mechanisms for the apparition and progression of diabetic neuropathy because the free radicals determine an increase rate of apoptosis of the peripheral neurons.
The levels of these lipoperoxides can be easily identified by determining the level of malondialdehyde in the blood, a product generated by the lipoperoxidation of the polyunsaturated fatty acids from the cells membranes . (4) Data from literature demonstrates that diabetic patents have a three times higher malondialdehyde concentration in the blood than patients without diabetes . In this (5) context antioxidant therapy represents a necessity; one of the substances that showed promising results was alpha lipoic-acid (ALA), which determined in many studies a reduction in the symptomatology of diabetic neuropathy because it has scavenger effect on free radicals . (6) Studiul a demonstrat că la pacien ii cu diabet zaharat stresul oxidativ este de 
Objectives
The present study had the objective to evaluate the oxidative stress in diabetic patients compared to healthy controls, to determine the effect that alpha lipoic-acid possess on oxidative stress in patients with diabetes mellitus, to determine its effect on chronic pain that is characteristic for diabetic neuropathy and also on the vibration perception threshold.
Material and method
In the study were included 24 patients with 
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The medication was administered for 10 days intravenously and then for 30 days by mouth.
The study had a duration of 50 days.
The study was composed of the following phases:
l screening phase 
The was considered statistically significant.
Results and discussions
Characteristics of patients with diabetes mellitus and without diabetes mellitus are described in table 2 Table . 9 HbA1C modification after ALA treatment Alpha lipoic acid was effective in decreasing oxidative stress as resulted in our study because it is a substance that increases reduced glutathione a substance that is produced in the body . Also alpha lipoic acid (7) acts as free radical scavenger . There are (7) numerous studies that confirm that alpha lipoic acid is effective in reducing diabetic 
A meta-analysis of studies concerning the efficacy of alpha lipoic acid therapy concludes that intravenous treatment produces significant improvement in painful diabetic neuropathy while oral treatment seems to be less effective . In our study (9) improvement in pain symptoms and vibration perception threshold continued after ending the intravenous therapy, starting the oral therapy and after its completion evaluating neuropathy characteristic. These results demonstrate that improvements in diabetic neuropathy achieved by intravenous ALA therapy can be maintained and further improved by starting ALA therapy per os.
Conclusion
Patients with diabetes mellitus have an increased level of oxidative stress compared with people with normal glucose metabolism.
In our study the level of oxidative stress as measured by lipoperoxids production was twice as high. Alpha lipoic acid produced a significant reduction in oxidative stress parameters, a decrease that lead to a significant improvement in pain intensity and vibration perception threshold in patients with painful diabetic neuropathy.
